Drug news
Vertex Pharma starts Phase IIIb trial in genoytpe 1 Hepatitis C patients who have 'CC' variation near the IL28B gene
Vertex Pharmaceuticals will initiate a Phase IIIb study called CONCISE that will evaluate the potential for treatment with Incivek (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the �CC' variation near the IL28B gene. Incivek is administered in combination with pegylated-interferon and ribavirin. Approximately one-third of people with hepatitis C have the �CC' genotype, which has been associated with higher sustained viral response (SVR, or viral cure) rates and faster response to interferon-based treatment. Incivek is now approved in the USA and EU.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins